Menlo Therapeutics, Inc.

Home » Menlo Therapeutics, Inc.

IPO

Menlo Therapeutics, Inc.

They are a late‑stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.

Symbol

MNLO

Price Range
TBD

Anticipated Shares
7,000,000

Effective Date
January 25, 2018

Underwriters
Jefferies, Piper Jaffray, Guggenheim Securities

To view the prospectus for Menlo Therapeutics, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253